Immune checkpoint inhibitors propelled the field of oncology with clinical responses in many
different tumor types. Superior overall survival over chemotherapy has been reported in …

Approximately 70% of cases of kidney cancer are localized or locally advanced at diagnosis.
Among patients who undergo surgery for these cancers, 30–35% will eventually develop …

Clear cell renal cell carcinoma (ccRCC) is the most common and lethal renal malignant
tumor in adults. The aim of the present study was to identify the key genes involved in …

Standard treatment for localized non-metastatic renal cell carcinoma (RCC) is radical or
partial nephrectomy. However, after radical surgery, patients with stage II-III have a …

Advances in understanding the mechanisms of tumour-induced immunosuppression have
led to the development of immune-checkpoint inhibitors in cancer patients, including those …

Renal cell carcinoma (RCC) is the prevalent form of kidney cancer in adults, with clear cell
renal carcinoma (ccRCC) being the predominant subtype. While surgical resection remains …

PURPOSE Tyrosine kinase inhibitors (TKIs) have been widely used in the management of
patients with metastatic renal cell carcinoma (RCC). However, the use of systemic therapies …

Circular RNAs (circRNAs) are a class of non‑coding RNAs formed by covalently closed
loops through back‑splicing and exon‑skipping. circRNAs have been confirmed to play a …

Abstract In 2018, there were 400,000 new cases of renal cell carcinoma (RCC) globally, with
175,000 deaths attributable to the disease. Three quarters of patients have potentially …

Background Necroptosis has been reported to play a critical role in occurrence and
progression of cancer. The dysregulation of long non-coding RNAs (lncRNAs) is associated …